Imagine waking up one day and looking at yourself in the mirror and seeing your reflection covered in scales of red and silver. Your skin is burning, itching, and never seems to calm down. But what hurts the most isn't the physical pain.It's the whispered comments, the judgmental stairs, and the unsolicited advice that make you feel like a walking exhibit. This is the reality for millions of people living with psoriasis, a chronic immune mediated condition often misunderstood as just a skin disorder. To beg ...

Core Viewpoint - Arcutis Biotherapeutics has announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium, aimed at improving the understanding and management of genital psoriasis, which significantly impacts patients' quality of life and interpersonal relationships [1][2][3]. Group 1: Consensus Statements and Guidelines - The consensus statements focus on three key areas: physical diagnosis and patient conversations, impact on quality of life and interpersonal relationships, and treatment decisions [1][2]. - Genital psoriasis affects approximately six million Americans and is often underreported and undertreated due to its sensitive nature [2][4]. - The Consortium's guidelines aim to normalize conversations about genital psoriasis and improve shared decision-making between clinicians and patients [3][5]. Group 2: Research and Methodology - A comprehensive literature review was conducted, analyzing 78 unique publications to formulate the consensus statements [2]. - The consensus was developed using a modified Delphi process, which included virtual meetings and anonymous surveys to gather feedback [2][3]. Group 3: Clinical Implications - Genital psoriasis should be recognized as a distinct diagnosis with a unique ICD-10-CM code to facilitate better diagnosis and treatment [5]. - Early diagnosis is critical, as the psychological burden and symptoms may worsen over time if not addressed promptly [5][10]. - The implementation of standardized assessment tools and comprehensive skin examinations is recommended to improve patient care [5][10]. Group 4: Company Overview - Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology, with a portfolio aimed at addressing immune-mediated dermatological diseases [6]. - The company is committed to developing differentiated therapies and has a robust pipeline for various inflammatory dermatological conditions [6].

Summary of T SCAN Therapeutics Conference Call Company Overview - The conference featured T SCAN Therapeutics, represented by CEO Gavin Macbeth, at BofA's 2025 health care conference [1] Core Insights and Arguments - T SCAN is developing a program called Orca 21, which aims to combine IL-23 and IL-17 therapies for psoriasis treatment. The strategy involves using IL-17 for rapid skin clearance followed by IL-23 for maintenance [3][4] - The company is currently in Phase 1 clinical trials for the Orca 1 program, with results expected in the second half of the year. A Phase 2 study will also commence in the same timeframe, with psoriasis data anticipated next year [5][6] - T SCAN has raised over $475 million last year, providing sufficient funding for ongoing clinical trials and a runway for an additional year without needing further capital [6] Key Upcoming Events - Key milestones include: - Phase 1 readout for Orca 1 in the second half of this year - Phase 2 study initiation for psoriasis in the second half of this year - Pharmacokinetic (PK) data expected in the first half of next year [5][6] Important Metrics - The company aims for a 50-day half-life for the molecule to enable six-month dosing and a 75-day half-life for annual dosing, which would be a significant advancement in treatment options [9][10] Additional Considerations - The combination therapy approach has garnered excitement from physicians, indicating potential market interest and acceptance [4] - The reproducibility of psoriasis data across trials is highlighted as a critical factor for the company's future success [5]